NCT02947152View on ClinicalTrials.gov

HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

December 1, 2016

Primary Completion Date

September 14, 2017

Study Completion Date

September 14, 2017

Conditions
Epithelial Ovarian CancerRenal Cell Carcinoma
Interventions
DRUG

HKT288

Cadherin-6-targeting antibody-drug conjugate for intravenous administration

Trial Locations (6)

3000

Novartis Investigative Site, Melbourne

Novartis Investigative Site, Leuven

6600

Novartis Investigative Site, Locarno

77030

Novartis Investigative Site, Houston

466 8560

Novartis Investigative Site, Nagoya

08035

Novartis Investigative Site, Barcelona

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY